What is Leerink Partnrs' Forecast for NAMS FY2028 Earnings?

NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) - Stock analysts at Leerink Partnrs upped their FY2028 EPS estimates for NewAmsterdam Pharma in a research note issued on Wednesday, November 6th. Leerink Partnrs analyst R. Ruiz now forecasts that the company will post earnings of $0.44 per share for the year, up from their prior estimate of $0.39. The consensus estimate for NewAmsterdam Pharma's current full-year earnings is ($2.06) per share.

NAMS has been the topic of several other reports. Needham & Company LLC restated a "buy" rating and set a $36.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday. Piper Sandler reaffirmed an "overweight" rating and issued a $37.00 price objective on shares of NewAmsterdam Pharma in a research report on Monday, September 23rd. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $31.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $33.80.

NewAmsterdam Pharma Stock Performance

NAMS traded up $0.86 during midday trading on Friday, reaching $23.50. 420,221 shares of the company were exchanged, compared to its average volume of 260,185. NewAmsterdam Pharma has a one year low of $8.64 and a one year high of $26.35. The company's fifty day moving average price is $17.51 and its 200 day moving average price is $18.49.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.30. The firm had revenue of $29.11 million for the quarter, compared to the consensus estimate of $5.35 million.

Hedge Funds Weigh In On NewAmsterdam Pharma

Large investors have recently modified their holdings of the business. Banque Cantonale Vaudoise bought a new position in NewAmsterdam Pharma in the 2nd quarter worth approximately $38,000. Rosalind Advisors Inc. purchased a new position in shares of NewAmsterdam Pharma in the second quarter valued at $194,000. Wolverine Asset Management LLC raised its stake in shares of NewAmsterdam Pharma by 117.7% during the 2nd quarter. Wolverine Asset Management LLC now owns 15,524 shares of the company's stock valued at $298,000 after purchasing an additional 8,394 shares during the period. Sei Investments Co. lifted its holdings in NewAmsterdam Pharma by 49.1% during the 2nd quarter. Sei Investments Co. now owns 24,561 shares of the company's stock worth $472,000 after purchasing an additional 8,087 shares in the last quarter. Finally, Lisanti Capital Growth LLC bought a new position in NewAmsterdam Pharma in the 3rd quarter worth about $700,000. Hedge funds and other institutional investors own 89.89% of the company's stock.

Insider Activity

In related news, CAO Louise Frederika Kooij sold 45,000 shares of NewAmsterdam Pharma stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $15.72, for a total value of $707,400.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 19.50% of the company's stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.